[Consensus of Chinese experts on the mobilization and collection of autologous hematopoietic stem cells in lymphoma (2020)].
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2020 Dec 14;41(12):979-983. doi: 10.3760/cma.j.issn.0253-2727.2020.12.002.
Abstract
摘要
相似文献
1
[Consensus of Chinese experts on the mobilization and collection of autologous hematopoietic stem cells in lymphoma (2020)].《中国淋巴瘤自体造血干细胞动员与采集专家共识（2020年版）》
Zhonghua Xue Ye Xue Za Zhi. 2020 Dec 14;41(12):979-983. doi: 10.3760/cma.j.issn.0253-2727.2020.12.002.
2
Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.培洛昔福联合粒细胞集落刺激因子（G-CSF）治疗淋巴瘤和多发性骨髓瘤患者：在自体造血干细胞动员时，G-CSF 联合或不联合化疗失败后的奥地利经验
Transfusion. 2011 May;51(5):968-75. doi: 10.1111/j.1537-2995.2010.02896.x. Epub 2010 Sep 28.
3
Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells.培洛昔芳联合粒细胞集落刺激因子可改善外周血循环中 CD34+细胞低的非霍奇金淋巴瘤患者造血干细胞的动员。
Biol Blood Marrow Transplant. 2013 Apr;19(4):670-5. doi: 10.1016/j.bbmt.2013.01.005. Epub 2013 Jan 17.
4
Mobilization of Hematopoietic Stem Cells for Hematopoietic Cells Autologous Transplantation with Use of Plerixafor.使用普乐沙福动员造血干细胞用于造血细胞自体移植
Ann Transplant. 2017 May 12;22:296-302. doi: 10.12659/aot.901875.
5
Plerixafor and granulocyte-colony-stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non-Hodgkin's lymphoma: a randomized Phase 3 study.普乐沙福与粒细胞集落刺激因子用于动员中国非霍奇金淋巴瘤患者造血干细胞以进行自体移植：一项随机3期研究
Transfusion. 2018 Jan;58(1):81-87. doi: 10.1111/trf.14426. Epub 2017 Dec 13.
6
Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.培洛昔福联合粒细胞集落刺激因子与安慰剂联合粒细胞集落刺激因子动员多发性骨髓瘤且外周血 CD34+细胞计数低的患者中的 CD34+造血干细胞：一项随机试验的亚组分析结果。
Biol Blood Marrow Transplant. 2012 Oct;18(10):1564-72. doi: 10.1016/j.bbmt.2012.05.017. Epub 2012 Jun 6.
7
A single center's experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation.一个中心在计划接受自体造血细胞移植的淋巴瘤患者中使用四种不同一线动员策略的经验。
Bone Marrow Transplant. 2017 Apr;52(4):561-566. doi: 10.1038/bmt.2016.304. Epub 2017 Jan 9.
8
Mobilization of hematopoietic progenitor cells for autologous transportation: consensus recommendations.用于自体移植的造血祖细胞动员：共识推荐
Rev Assoc Med Bras (1992). 2016 Oct;62 Suppl 1:10-15. doi: 10.1590/1806-9282.62.suppl1.10.
9
Hematopoietic Progenitor Cell Mobilization for Autologous Stem Cell Transplantation in Multiple Myeloma in Contemporary Era.多发性骨髓瘤自体干细胞移植中造血祖细胞动员的当代策略。
Clin Lymphoma Myeloma Leuk. 2019 Apr;19(4):200-205. doi: 10.1016/j.clml.2018.12.010. Epub 2018 Dec 20.
10
Toward a more rational policy for autologous hematopoietic stem cell mobilization.迈向更合理的自体造血干细胞动员政策。
Biol Blood Marrow Transplant. 2012 Oct;18(10):1468-70. doi: 10.1016/j.bbmt.2012.08.001. Epub 2012 Aug 11.
引用本文的文献
1
The impact of multiple myeloma drugs treatments on autologous stem cell transplantation in the era of new drugs.新药时代多发性骨髓瘤药物治疗对自体干细胞移植的影响
Front Oncol. 2025 Feb 14;15:1479164. doi: 10.3389/fonc.2025.1479164. eCollection 2025.
2
Plerixafor-based mobilization and mononuclear cell counts in graft increased the risk of engraftment syndrome after autologous hematopoietic stem cell transplantation.基于普乐沙福的动员及移植物中单核细胞计数增加了自体造血干细胞移植后植入综合征的风险。
Blood Sci. 2024 May 16;6(3):e00190. doi: 10.1097/BS9.0000000000000190. eCollection 2024 Jul.
3
Analysis of Factors Affecting Hematopoietic Stem Cell Mobilization Efficiency and Early Hematopoietic Reconstruction Indicators during Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation.自体外周血造血干细胞移植中影响造血干细胞动员效率及早期造血重建指标的因素分析
Glob Med Genet. 2024 Apr 18;11(2):159-166. doi: 10.1055/s-0044-1786006. eCollection 2024 Jun.
4
A novel PEGylated form of granulocyte colony-stimulating factor, mecapegfilgrastim, for peripheral blood stem cell mobilization in patients with hematologic malignancies.一种新型聚乙二醇化的粒细胞集落刺激因子，美泊利珠单抗，用于血液系统恶性肿瘤患者的外周血造血干细胞动员。
BMC Cancer. 2023 Jul 24;23(1):694. doi: 10.1186/s12885-023-11197-3.
本文引用的文献
1
A retrospective study of autologous stem cell mobilization by G-CSF in combination with chemotherapy in patients with multiple myeloma and lymphoma.一项关于粒细胞集落刺激因子（G-CSF）联合化疗用于多发性骨髓瘤和淋巴瘤患者自体干细胞动员的回顾性研究。
Oncol Lett. 2020 Jan;19(1):1051-1059. doi: 10.3892/ol.2019.11177. Epub 2019 Dec 3.
2
Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor.对欧洲血液与骨髓移植学会（EBMT）登记处收集的一组接受普乐沙福治疗的淋巴瘤患者的数据进行分析。
Bone Marrow Transplant. 2020 Mar;55(3):613-622. doi: 10.1038/s41409-019-0693-z. Epub 2019 Sep 30.
3
Orchestration of Chemomobilization and G-CSF Administration for Successful Hematopoietic Stem Cell Collection.化疗法动员和 G-CSF 给药在成功造血干细胞采集中的协同作用。
Biol Blood Marrow Transplant. 2018 Jun;24(6):1281-1288. doi: 10.1016/j.bbmt.2018.01.007. Epub 2018 Jan 17.
4
Plerixafor and granulocyte-colony-stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non-Hodgkin's lymphoma: a randomized Phase 3 study.普乐沙福与粒细胞集落刺激因子用于动员中国非霍奇金淋巴瘤患者造血干细胞以进行自体移植：一项随机3期研究
Transfusion. 2018 Jan;58(1):81-87. doi: 10.1111/trf.14426. Epub 2017 Dec 13.
5
A single center's experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation.一个中心在计划接受自体造血细胞移植的淋巴瘤患者中使用四种不同一线动员策略的经验。
Bone Marrow Transplant. 2017 Apr;52(4):561-566. doi: 10.1038/bmt.2016.304. Epub 2017 Jan 9.
6
Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients.普乐沙福在一线干细胞动员方面优于传统化疗，甚至在经过大量预处理的患者中也有效。
Blood Cancer J. 2014 Oct 31;4(10):e255. doi: 10.1038/bcj.2014.79.
7
Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.多发性骨髓瘤和淋巴瘤患者的自体造血干细胞动员：欧洲血液与骨髓移植组的立场声明
Bone Marrow Transplant. 2014 Jul;49(7):865-72. doi: 10.1038/bmt.2014.39. Epub 2014 Mar 31.
8
Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.优化自体干细胞动员策略以改善患者结局：共识指南和建议。
Biol Blood Marrow Transplant. 2014 Mar;20(3):295-308. doi: 10.1016/j.bbmt.2013.10.013. Epub 2013 Oct 17.
9
Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma.≥60 岁和<60 岁非霍奇金淋巴瘤或多发性骨髓瘤患者中， upfront 培洛利昔+G-CSF 与安慰剂+G-CSF 动员 CD34(+)造血祖细胞的安全性和有效性。
Am J Hematol. 2013 Dec;88(12):1017-23. doi: 10.1002/ajh.23561. Epub 2013 Sep 9.
10
Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone.化疗联合粒细胞集落刺激因子（G-CSF）与单纯使用G-CSF进行自体干细胞动员的效果及成本比较。
Bone Marrow Transplant. 2013 Nov;48(11):1444-9. doi: 10.1038/bmt.2013.80. Epub 2013 Jun 10.
Zotero 插件